Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Shares Outstanding (Weighted Average) (2022 - 2025)

Oramed Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $41.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) changed N/A year-over-year to $41.4 million; the TTM value through Dec 2025 reached $41.4 million, changed N/A, while the annual FY2025 figure was $41.4 million, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) reached $41.4 million in Q4 2025 per ORMP's latest filing, down from $41.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $41.8 million in Q3 2025 to a low of $38.7 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 4 years is $40.3 million, with a median of $40.3 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): rose 3.85% in 2023, then grew 0.96% in 2025.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $39.0 million in 2022, then grew by 3.38% to $40.3 million in 2023, then grew by 1.41% to $40.9 million in 2024, then grew by 1.27% to $41.4 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Shares Outstanding (Weighted Average) are $41.4 million (Q4 2025), $41.8 million (Q3 2025), and $41.7 million (Q2 2025).